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ABSTRACT
The HMG-domain transcription factor Sox10 is
expressedthroughoutoligodendrocytedevelopment
and is an important component of the transcriptional
regulatory network inthese myelin-forming CNSglia.
Of the known Sox10 regulatory regions, only the evo-
lutionary conserved U2enhancer inthe distal50-flank
of the Sox10 gene exhibits oligodendroglial activity.
We found that U2 was active in oligodendrocyte pre-
cursors, but not in mature oligodendrocytes. U2
activity also did not mediate the initial Sox10 induc-
tion after specification arguing that Sox10 expres-
sion during oligodendroglial development depends
on the activity of multiple regulatory regions. The
oligodendroglial bHLH transcription factor Olig2,
but not the closely related Olig1 efficiently activated
the U2 enhancer. Olig2 bound U2 directly at several
sites including a highly conserved one in the U2 core.
Inactivation of this site abolished the oligodendro-
glial activity of U2 in vivo. In contrast to Olig2, the
homeodomain transcription factor Nkx6.2 repressed
U2 activity. Repression may involve recruitment of
Nkx6.2 to U2 and inactivation of Olig2 and other ac-
tivators by protein–protein interactions. Considering
the selective expression of Nkx6.2 at the time of spe-
cification and in differentiated oligodendrocytes,
Nkx6.2 may be involved in limiting U2 activity to the
precursor stage during oligodendrocyte
development.
INTRODUCTION
Development of a differentiated cell from a pluripotent
precursor is regulated by a complex network of transcrip-
tion factors that interact in many ways and inﬂuence each
other’s expression and activity. In the central nervous
system (CNS), many different neuronal and glial cell
types have to be generated from a common pool of pre-
cursor cells. Oligodendrocytes represent one of these glial
cell types. In the white matter, they form myelin sheaths
around axons and thereby allow rapid saltatory conduc-
tion along the axon.
In recent years, much has been learnt about the origin
of oligodendrocytes and the stages of their development
during vertebrate and particularly during mammalian
embryogenesis (1). In the mouse spinal cord, oligodendro-
cyte precursors (OLPs) are predominantly derived from
neuroepithelial cells in a well-deﬁned region of the
ventral part of the ventricular zone (2). From this pMN
domain, speciﬁed OLPs colonize the spinal cord paren-
chyma, accumulate preferentially at the end of embryo-
genesis in the marginal zone as the future white matter
where they start to undergo terminal differentiation and
express myelin genes before eventually providing myelin
sheaths to axons from several neurons.
Several transcription factors have been identiﬁed that
are expressed in developing and mature oligodendrocytes
(3,4). These include bHLH, homeodomain, zinc ﬁnger and
high-mobility group (HMG) domain proteins. They are
required for various aspects of oligodendrocyte develop-
ment including speciﬁcation, identity, survival, lineage
progression and terminal differentiation. The bHLH
protein Olig2 and the HMG domain transcription factor
Sox10 are particularly important. Olig2 is already
expressed in neuroepithelial cells before speciﬁcation and
continues to be present throughout oligodendroglial
development. OLPs are absent in the spinal cord of
Olig2-deﬁcient mice, pointing to the essential role of
Olig2 during the early phases of oligodendroglial devel-
opment (5,6). Deletion of the closely related and
co-expressed Olig1, in contrast, rather causes a terminal
differentiation defect arguing that Olig1 and Olig2
function predominantly during different phases of oligo-
dendroglial development (7,8). One of the genes that is
induced immediately after oligodendroglial speciﬁcation
is Sox10 (5,6). Once induced, Sox10 remains present in
oligodendroglia (9,10) where it ﬁrst ensures OLP
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drives terminal differentiation as a direct activator of
myelin gene expression (10).
Although much has been learnt about the function of
single transcription factors, only few data exist on the
interplay of these factors and their cross-regulations
within the oligodendroglial transcriptional network.
Recently, we have identiﬁed an enhancer  36kb
upstream of the mouse Sox10 gene that is capable of
driving transgene expression in oligodendroglia (12).
This enhancer was also active in several other glial cell
types of the peripheral nervous system (PNS), including
Schwann cells and satellite glia, but not in enteric glia.
Here, we focused on the oligodendroglial activity of this
enhancer to determine how Sox10 expression is regulated
in the oligodendrocyte lineage and how it is inﬂuenced by
other components of the oligodendroglial transcriptional
network.
MATERIALS AND METHODS
Transgenic animals
Sox10
lacZ/+ mice in which Sox10 coding sequences were
replaced on one allele by lacZ marker sequences, and mice
carrying the lacZ transgene under control of the hsp68
minimal promoter and the mouse U2 enhancer
(U2-lacZ) have been described before (12,13).
U2mut-lacZ resembled the previously described
U2-lacZ transgene except for the presence of an
inactivating mutation in the Olig2 binding site bHLH4
(Figure 4A). After separation from the vector backbone
and puriﬁcation, the U2mut-lacZ transgene was micro-
injected as a SpeI/KpnI fragment into the male pronucleus
of fertilized FVB oocytes. Transgenic mice were generated
from injected oocytes according to standard techniques.
Founder mice and transgenic offspring were identiﬁed
and genotyped by PCR analysis of DNA prepared from
tail biopsies using the U2-speciﬁc forward primer 50-GGC
ACAGAAAGGTCTCTTTG-30 and the lacZ-speciﬁc
reverse primer 50-AGTAGCTGTCAGCGTCTGGT-30 as
described previously (12).
Tissue preparation, histological staining,
immunohistochemistry and documentation
Embryos from 11.5 days post-coitum (dpc) to 16.5 dpc,
newborn (P1) to 14-day-old (P14) pups and adult mice
were sacriﬁced and underwent ﬁxation in 1 or 4%
paraformaldehyde depending on their further use. After
ﬁxation, whole embryos and tissues were immediately
stained for b-galactosidase activity or were cryoprotected
in sucrose and frozen at  80 C in tissue freezing medium
(Leica, Bensheim, Germany) in preparation for cryotome
sectioning.
Detection of b-galactosidase activity was performed
after ﬁxation in 1% paraformaldehyde on whole mount
embryos (11.5 dpc) or 20mm transverse cryosections by
incubation in 1% X-gal for several hours at 37 C.
For immunohistochemistry, 10mm cryotome sections
from the forelimb level of genotyped, age-matched mouse
embryos and pups were incubated with the following
primary antibodies: anti-b-galactosidase goat antiserum
(1:500 dilution, Biotrend), anti-Olig2 rabbit antiserum
(1:1000 dilution, Chemicon), anti-Olig1 rabbit antiserum
(1:5000 dilution, gift of C. Stiles, Dana-Farber Cancer
Institute, Boston, MA, USA) anti-PDGFR-a rabbit anti-
serum (1:80 dilution, NeoMarkers), anti-MBP rabbit anti-
serum (1:200 dilution, NeoMarkers), anti-Sox10 guineapig
antiserum [1:1000 dilution (14)], anti-Nkx6.2 guinea pig
antiserum (1:1000 dilution, gift of J. Ericson, Karolinska
Institutet, Stockholm, Sweden), anti-Nkx2.2 mouse mono-
clonal (1:400 dilution, Developmental Studies Hybridoma
Bank, Iowa City, IA, USA) and anti-NeuN mouse mono-
clonal (1:600 dilution, Chemicon). Secondary antibodies
conjugated to Cy2 and Cy3 immunoﬂuorescent dyes
(Dianova) were used for detection. In case of Nkx2.2
antibodies, signal intensity was ampliﬁed using the
TSA
TM
-Plus Cy3 System (Perkin Elmer, Boston, MA,
USA).
Samples were analyzed and documented either with a
Leica inverted microscope (DMIRB) equipped with a
cooled MicroMax CCD camera (Princeton Instruments,
Trenton, NJ, USA) or with a Leica MZFLIII stereomicro-
scope equipped with an Axiocam (Zeiss, Oberkochem,
Germany).
Plasmids
All expression plasmids were derived from pCMV5 and
thus carried coding sequences under control of the cyto-
megalovirus immediate early promoter. The eukaryotic
pCMV5 expression plasmid for myc-tagged Olig2 has
been described previously (15). Using a similar strategy,
coding sequences for full-length Olig1 and different Olig2
fragments (amino acids 2–180, amino acids 181–323)
were cloned as BamHI/BglII fragments behind a
myc-tag into the BglII site of pCMV5-myc. Untagged
versions of Olig1 (accession number NM_021770.3) and
Olig2 (accession number NM_016967.2) (16) were inserted
into pCMV5 as KpnI/EcoRI and SmaI fragments,
respectively. The full-length Nkx6.2 open reading frame
(accession number NM_183248.2) was ampliﬁed by PCR
and placed into pCMV5 as T7-tagged and untagged
version using BamHI and HindIII sites. Nkx6.2 fragments
coding for amino acids 1–133, amino acids 134–216 and
amino acids 134–277 were inserted as T7-tagged versions
only. The E47 coding sequence (accession number
BC018260.1, gift of Jonas Muhr, Karolinska Institutet,
Stockholm, Sweden) was placed between BglII and
HindIII sites of pCMV5. Coding sequences for Nkx2.2
and Nkx6.1 were transferred into pCMV5 from corres-
ponding pcDNA3 and pCAGG expression plasmids
(gifts of L. Sussel, Columbia University, New York,
NY, USA and J. Ericson, Karolinska Institutet,
Stockholm, Sweden). For reporter gene assays the
U2-luc plasmid was used. It contained the luciferase
reporter gene under control of the 0.67kb U2 region
(12) upstream of the b-globin minimal promoter.
Transcription factor binding sites within U2 were
mutated using the QuickChange XL Site-directed
Mutagenesis Kit (Stratagene, La Jolla, CA, USA).
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EMSA and co-immunoprecipitation
HEK293 cells were maintained in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 10% fetal calf
serum (FCS) and transfected by the polyethylenimine
(PEI) technique using 10mg pCMV5-based expression
plasmid per 100-mm plate. Cells were harvested 48 h
post-transfection for extract preparation (17) and ectopic
expression of the respective transcription factor was
veriﬁed by western blotting using anti-myc tag (1:10000
dilution, Cell Signaling Technology) or anti-T7 tag
(1:10000 dilution, Novagen) mouse monoclonals. With
these extracts, electrophoretic mobility shift analyses
(EMSA) were performed as described (18) using
32P-labeled 25-bp double-stranded oligonucleotides
containing putative Olig2 or Nkx6.2 binding sites (for
sequences, see Figure 5A). In supershift experiments,
antibodies were used in a 1:40 dilution and pre-incubated
for 30min with the protein extracts before addition of
32P-labeled oligonucleotide probes.
Coimmunoprecipitations were carried out with
HEK293 protein extracts diluted 1:5 in TEN buffer
(100mM EDTA, 100mM NaCl, 0.5% NP-40, 20mM
Tris, pH 7.4, 10mg/ml aprotinin, 10mg/ml leupeptin,
2mM dithiothreitol). Tagged proteins were precipitated
overnight at 4 C using monoclonal antibodies directed
against the tag and protein G sepharose beads. After sep-
aration from the supernatant and three consecutive
washing steps with TEN buffer, precipitated proteins
were eluted from protein G sepharose beads and
detected by western blot analysis.
Luciferase assay
Rat 33B oligodendroglioma cells were maintained in
DMEM containing 10% FCS and transfected with
SuperFect Transfection Reagent (Qiagen, Hilden,
Germany) on 24-well tissue culture plates using varying
amounts (25–500ng, usually 100ng) of pCMV5-based
expression vectors and 500ng of luciferase reporter
plasmid. Cells were harvested 48h post-transfection.
Luciferase activity was determined in the presence of
luciferin substrate by detection of chemiluminescence.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed
as described (19) on 33B cells transfected with
pCMV5-myc-Olig2 or pCMV-T7-Nkx6.2, and on dis-
sected, trypsinized spinal cord of 18.5 dpc-old mouse
embryos. Proteins were cross-linked to DNA in 1% for-
maldehyde. After addition of glycine, chromatin was
prepared and sheared to an avarage fragment length of
300–600bp using a Sonoplus HD2070 homogenisator
(Bandelin, Berlin, Germany). Immunoprecipitations were
performed overnight at 4 C using monoclonal a-myc-tag
or a-T7-tag IgG (for 33B cells) or polyclonal a-Olig2
antibodies (for spinal cords) as well as control preimmune
serum and protein G sepharose beads. DNA was puriﬁed
from input and precipitated chromatin after cross-link
reversal and subjected to PCR. The following primer
pairs were used for detection in 33 cycles of standard
PCR using an annealing temperature of 57 C: 50-CGAC
AGCCCGTACAGCTGC-30 and 50-GTGACTGAGAGT
CTGAGAGC-30 for rat U2,5 0-CGACAGCCCCTACAG
CTGC-30 and 50-GTGACTGAGAGTCTGAGAGC-30
for mouse U2,5 0-CTAGGCAAGCACTCTGTCAA-30
and 50-GCCTCAGCATGGTTCTAGTT-30 for the rat
genomic control region and 50-GCAGACAGCAGTTG
GAGACC-30 and 50-CCTGTGCCCAGACTCTTGTT-30
for mouse U5 (12).
RESULTS
Expression of the Sox10 U2 enhancer in the developing
spinal cord occurs predominantly in OLPs
Among the previously identiﬁed Sox10 enhancers, U2 was
the only one active in oligodendroglial cells (12). In the
original study, experiments were performed on spinal
cords of 16.5 dpc-old embryos. At this stage, oligodendro-
cyte speciﬁcation is already over and most oligodendro-
glial cells are in the OLP stage. It is thus not clear from the
published data whether U2 fully recapitulates the expres-
sion pattern of Sox10 which is turned on immediately
after the speciﬁcation event in OLPs and remains ex-
pressed in mature oligodendrocytes (10).
We, therefore, compared the U2-lacZ expression
pattern in the spinal cord at various days of embryonic
and post-natal development with lacZ expression from the
Sox10
lacZ allele that faithfully mimicks Sox10 expression
(13). Whereas OLPs were already visible at 12.5 dpc by
X-gal staining near the pMN domain in spinal cords of
Sox10
+/lacZ embryos (Figure 1A, arrow), age-matched
spinal cords of U2-lacZ transgenic embryos exhibited no
X-gal staining within the spinal cord (Figure 1B). In
contrast, X-gal staining was comparable in both geno-
types outside the spinal cord in dorsal root ganglia and
along peripheral nerves (Figure 1A and B). At 12.75 dpc
X-gal staining started to become detectable in U2-lacZ
transgenic embryos but only in Sox10-positive cells that
had migrated some distance from the ventricular zone
(Figure 2A and A0). At 14.5 dpc, a high number of
lacZ-positive cells was detectable in U2-lacZ and
Sox10
+/lacZ embryos (Figure 1C and D). In both geno-
types, OLPs were stained throughout the spinal cord par-
enchyma. In Sox10
+/lacZ embryos, the origin of OLPs was
still marked by a particular high density of X-gal stained
cells near the pMN domain (Figure 1C, arrow). This
staining was again missing in the U2-lacZ embryos
(Figure 1D). Compared to lacZ expression in
Sox10
+/lacZ embryos, the U2-lacZ transgene is thus
turned on in the oligodendrocyte lineage with delay.
At 16.5 dpc and P1, the staining pattern of spinal cords
from Sox10
+/lacZ and U2-lacZ mice were very similar
with OLPs being detected throughout the spinal cord
(Figure 1E–H). At P1, OLP density was higher in the
ventral marginal zone as the future white matter region
where terminal differentiation of oligodendrocytes starts
at this time (Figure 1G and H, arrowheads). Closer inspec-
tion revealed that the difference between staining of the
marginal zone and the remainder of the parenchyma was
1282 Nucleic Acids Research, 2011,Vol.39, No. 4more pronounced in Sox10
+/lacZ than in U2-lacZ mice
(Figure 1G and H). There are two reasons for the more
intense X-gal staining in the marginal zone. On the one
hand, the density of oligodendroglial cells is higher. On
the other, oligodendroglia in this region start terminal
differentiation and upregulate Sox10 during the process
(10). As we did not ﬁnd any signiﬁcant difference in
overall oligodendroglial numbers in the marginal zone of
Sox10
+/lacZ and U2-lacZ spinal cords (data not shown),
activity of the U2 enhancer is probably not upregulated
during terminal differentiation.
At later post-natal stages, U2-lacZ activity is drastically
downregulated compared to Sox10
lacZ activity. Whereas
spinal cords of P14-old Sox10
+/lacZ mice exhibited intense
X-gal staining throughout the spinal cord with particular-
ly high levels in the white matter, there were only a few
remaining X-gal positive cells in age-matched spinal cords
of U2-lacZ mice (Figure 1I and J). As most oligodendro-
glia have converted from OLPs to myelinating oligo-
dendrocytes at this time, we conclude that U2 activity is
turned off during terminal differentiation. U2 thus con-
tributes to Sox10 expression in the oligodendrocyte
lineage during a particular time window only.
So far, our conclusions are based on the X-gal staining
pattern. To conﬁrm that the stained cells indeed
represent oligodendroglia, we additionally performed
co-immunohistochemistry with antibodies directed
against b-galactosidase (Figure 2). This conﬁrmed the
absence of U2-lacZ transgene expression at 12.5 dpc
(data not shown). At 12.75 dpc, the ﬁrst b-galactosidase-
positive cells became detectable in U2-lacZ spinal cords in
the vicinity of the pMN domain (Figure 2B0). These cells
were farther away from the pMN domain than
b-galactosidase-positive cells in age-matched Sox10
+/lacZ
spinal cords (Figure 2B) in agreement with the X-gal
staining pattern (Figure 2A and A0). They were fewer
and represented only a fraction of the Sox10-positive
cells, whereas b-galactosidase labeled all Sox10-positive
cells in Sox10
+/lacZ spinal cords (Figure 2B and B0). As
the Sox10-positive cells without b-galactosidase in the
U2-lacZ spinal cords were the ones closer to the pMN
domain, we conclude that b-galactosidase expression is
delayed in newly speciﬁed OLPs relative to Sox10
expression.
At 14.5 dpc and 16.5 dpc, the b-galactosidase staining
pattern was very similar in U2-lacZ and Sox10
+/lacZ spinal
cords (Figure 2F–J and F0–J0 and data not shown). In both
genotypes, b-galactosidase-positive cells in the spinal cord
were also stained with antibodies against Sox10, Olig2 and
Olig1 as markers for cells of the oligodendrocyte lineage
(Figure 2F, F0,G ,G 0, H and H0 and data not shown).
There was also a near complete overlap with PDGFRa,
a marker for OLPs (Figure 2I and I0 and data not shown).
This was expected, as virtually all oligodendroglia are
OLPs at various stages of their development at this time.
A fraction of the b-galactosidase-positive cells in
the marginal zone also expressed Nkx2.2 at 16.5 dpc
(Figure 2J and J0). These cells represent late-stage
OLPs (11,20).
At P1, b-galactosidase-positive cells still expressed
Sox10, Olig2 and Olig1 (Figure 2K, K0,L ,L 0, M and
M0). More than 90% of all b-galactosidase-positive cells
were also labeled by antibodies directed against Nkx2.2
(Figure 2O and O0). In the marginal zone of spinal cords
from Sox10
+/lacZ mice, there were now b-galactosidase-
positive cells that also expressed MBP as a marker
for terminally differentiating and differentiated oligo-
dendrocytes (Figure 2N). These cells were also found in
U2-lacZ mice (Figure 2N0). Nkx6.2 is expressed in the
Figure 1. The U2-lacZ transgene is expressed in embryonic and early
post-natal spinal cord. LacZ expression was detected colorimetrically
using X-gal substrate on transverse sections from the forelimb level
of Sox10
lacZ/+ (A, C, E, G and I) and age-matched U2-lacZ
(B, D, F, H and J) mice at 12.5 dpc (A and B), 14.5 dpc (C and D),
16.5 dpc (E and F), P1 (G and H) and P14 (I and J). The pMN domain
as the main origin for spinal cord OLPs is highlighted in A and C by
an arrow. Arrowheads in G and H point to the marginal zone. No lacZ
staining was detected in wild-type littermates under identical
conditions. Size bars correspond to 200mm.
Nucleic Acids Research,2011, Vol.39, No. 4 1283Figure 2. Expression of the U2-lacZ transgene is restricted to OLPs in the embryonic and early post-natal spinal cord. (A and A0) The location of the
pMN domain (boxed area) was determined on transverse sections from the forelimb level of Sox10
lacZ/+ (A) and U2-lacZ (A0) embryos at 12.75 dpc
by X-gal staining. (B–O and B0–O0) Co-immunohistochemistry was performed on transverse spinal cord sections (forelimb level) of Sox10
lacZ/+(B–O)
and age-matched U2-lacZ (B0–O0) mice at 12.75 dpc (B and B0), 16.5 dpc (C, C0,F ,F 0,G, G0,H, H0,I ,I 0, J and J0), P1 (K, K0,L, L0,M ,M 0,N ,N 0,O
and O0), P3 (D and D0) and P10 (E and E0) using antibodies directed against b-galactosidase (in green) in combination with antibodies directed
against Sox10 (B, B0,F ,F 0, K and K0), Nkx6.2 (C, C0,D ,D 0,E ,E 0), Olig2 (G, G0, L and L0), Olig1 (H, H0, M and M0), PDGFRa (I, I0), Nkx2.2
(J, J0, O and O0) and MBP (N, N0) as oligodendroglial markers (all in red). Nuclei in B and B0 were counterstained with Dapi (blue). Pictures were
taken from the following regions: pMN domain (B and B0), mantle zone (F, F0,G ,G 0,H ,H 0, I and I0) and ventral marginal zone (C, C0,D ,D 0,E ,
E0,J ,J 0,K ,K 0,L ,L 0,M ,M 0,N ,N 0, O and O0). Size bars correspond to 200mm (A and A0) and 25mm (B–O and B0–O0).
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terminal differentiation (21,22). From late embryogenesis
onwards, Nkx6.2 thus selectively marks mature oligo-
dendrocytes (20). In agreement, there was no Nkx6.2
expression at 16.5 dpc in b-galactosidase-positive cells
of Sox10
+/lacZ and U2-lacZ spinal cords (Figure 2C and
C0). At P3, Nkx6.2 was found in a fraction of
b-galactosidase-positive cells in the marginal zone
(Figure 2D and D0). In Sox10
+/lacZ spinal cords, the
double-positive cells corresponded to cells with high
b-galactosidase expression levels in agreement with
b-galactosidase upregulation during oligodendroglial
differentiation (Figure 2D). In U2-lacZ spinal cords, in
contrast, b-galactosidase expression was lower in
Nkx6.2-positive cells than in Nkx6.2-negative oligo-
dendroglia (Figure 2D0). By P10, b-galactosidase had
disappeared from Nkx6.2-positive oligodendrocytes in
U2-lacZ spinal cords altogether (Figure 2E0), whereas
>98% of Nkx6.2-positive cells expressed b-galactosidase
in Sox10
+/lacZ spinal cords (Figure 2E). Taken together,
these results argue that the U2 enhancer may still be active
for a short time at the onset of terminal differentiation
before being turned off. Alternatively, b-galactosidase
protein persists for some time after its expression has
already ceased.
The Sox10 U2 enhancer is activated by Olig2 and
repressed by Nkx6.2 in cell culture
Having determined the temporal expression pattern of the
U2 enhancer, we searched for activating transcription
factors. Olig2 was an interesting candidate as this class
B bHLH protein is not only essential for oligodendrocyte
speciﬁcation, but continues to be expressed in OLPs and
even in terminally differentiating oligodendrocytes (5,6).
More importantly, chicken neural tube electroporation
studies had placed Olig2 genetically upstream of Sox10
(6,23).
To analyze whether Olig2 is able to inﬂuence U2
activity, we performed transient transfections with a
U2-luc reporter in 33B oligodendroglioma cells which en-
dogenously express Sox10 and Olig2 (data not shown).
Whereas co-transfection of the U2-luc reporter with
increasing amounts of an empty expression plasmid did
not change luciferase activities, a small but reproducible
increase in luciferase activity was observed after
co-transfection of Olig2 (Figure 3A). Similar slight in-
creases of luciferase reporter gene activity were obtained
in co-transfection with the Class A bHLH protein E47. As
Olig2 and E47 have been shown to physically interact and
as class A and Class B bHLH proteins often function as
heterodimers in vivo (24,25), we also analyzed the effect of
combined Olig2 and E47 on U2 enhancer activity.
Intriguingly, we now obtained a robust induction of U2
activity that ranged from 8- to 20-fold depending on
the amounts of co-transfected expression plasmids
(Figure 3A).
Co-transfection of Nkx2.2 with the U2-luc reporter
resulted in a mild increase in U2 activity (Figure 3B).
There was furthermore no additive or synergistic increase
of U2 activity when Nkx2.2 was combined with Olig2 and
E47 (data not shown). While this leaves open the possibil-
ity that Nkx2.2 contributes to U2 activity in late stage
OLPs, Olig2 clearly appears to be the more potent activa-
tor in combination with its E47 heterodimerization
partner. This ﬁts well with the established in vivo relation-
ships between Sox10, Nkx2.2 and Olig2 (26).
Figure 3. U2 activity in transiently transfected oligodendroglioma cells
is modulated by the presence of Olig2 and Nkx6.2. Transient transfec-
tions were performed in 33B cells with a luciferase reporter under
control of the Sox10 U2 enhancer and the b-globin minimal
promoter (U2-luc). Empty pCMV expression plasmids ( ) or expres-
sion plasmids for Olig2 (A and C), E47 (A), Nkx6.2 (B and C), Nkx6.1
(B), Nkx2.2 (B) and various combinations thereof (A and C) were
co-transfected as indicated below the bars. Increasing amounts of ex-
pression plasmid were used as indicated by the triangles (Olig2, Nkx6.2,
Nkx6.1 and Nkx2.2) and + versus + + (E47). Luciferase activities in
extracts from transfected cells were determined in three experiments
each performed in duplicates. The luciferase activity obtained for
U2-luc in the absence of ectopic transcription factor was arbitrarily
set to 1. Fold inductions in the presence of transcription factors were
calculated and are presented as mean±SD. High statistical signiﬁcance
(P 0.001) was obtained for activation rates obtained by Olig2 and E47
and for repression rates obtained by Nkx6.2 or Nkx6.1 as determined
by Student’s t-test.
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cells, Nkx6.2 decreased U2 activity in a concentration-
dependent manner (Figure 3B). The closely related
Nkx6.1 acted similarly, but was less effective
(Figure 3B). Interestingly, Nkx6.2 did not only decrease
basal U2 activity, which is likely dependent on the en-
dogenous Olig2 in 33B cells. It also counteracted the
increased U2 activity obtained after co-transfection of
Olig2 (Figure 3C). It therefore appears plausible that
Nkx6.2 may inhibit U2 activity during those phases of
oligodendrocyte development where it is expressed, i.e.
in differentiated oligodendrocytes and around the time
of oligodendroglial speciﬁcation (20–22). Nkx6.1 may
support Nkx6.2 in its repressive function at the time of
oligodendroglial speciﬁcation when both factors are
co-expressed.
The Sox10 U2 enhancer contains binding sites for Olig2
and Nkx6.2
To understand the mechanism by which Olig2 and Nkx6.2
may inﬂuence the activity of the U2 enhancer, we searched
its sequence for potential binding sites. Within the region
present in our U2 constructs, six sites were identiﬁed with
similarity to a bHLH consensus binding site (Figure 4A).
These sites were designated bHLH1–bHLH6. Of these
sites, only bHLH4 and bHLH5 were present in the U2
core that exhibits strong evolutionary conservation
between mammals and birds. bHLH1, bHLH2 and
bHLH3, in contrast, were located in the upstream ﬂank.
This is still well conserved among mammals, but not
between mammals and birds. bHLH6 was in the
30-ﬂank. Sequence conservation of the sites corresponded
to overall sequence conservation of their environment.
Only bHLH4 and bHLH5 exhibited full conservation in
mammals and birds. Sites bHLH2 and bHLH6 were
conserved in all mammals, whereas bHLH1 was only iden-
tical in mice and humans and bHLH3 exhibited conserva-
tion in rodents only.
All sites were tested by EMSA for their Olig2-binding
ability. However, only bHLH1, bHLH2 and bHLH4
yielded speciﬁc complexes with extracts containing
myc-tagged Olig2 (Figure 4C and data not shown). The
presence of Olig2 within the complex was conﬁrmed by
supershift with myc-tag antibodies (Figure 4D).
Interestingly, all three sites bound Olig2 more strongly
than the closely related Olig1 (Figure 4C). In the
presence of similar amounts of protein, bHLH2 and
bHLH4 yielded only faint complexes with Olig1. With
bHLH1, no Olig1-speciﬁc complex was observed. In
agreement with the poorer binding ability, Olig1 induced
the U2-luc reporter only marginally even in combination
with E47 (Figure 4B).
Within the U2 enhancer we also detected two potential
binding sites for Nkx6.2 (Figure 4A). Site GTX1 was
present in the U2 core and highly conserved, GTX2 in
contrast was in the less conserved 30-ﬂank. In EMSA,
none of the two sites bound signiﬁcant amounts of
full-length Nkx6.2 (Figure 4E). However, even the
HoxA5/A6 positive control oligonucleotide with its
high-afﬁnity binding site for Nkx6.2 (27) bound very
little full-length Nkx6.2. Therefore, we switched to a
shortened version of Nkx6.2 that consisted of amino
acids 134–216 and essentially corresponded to the
homeodomain (Figure 6A). With this shortened Nkx6.2
protein, we obtained protein–DNA complexes both for
GTX1 and GTX2 (Figure 4E). Compared to the
HoxA5/A6 positive control, less complex was formed
with GTX1 and even less with GTX2 suggesting that the
three sites bind Nkx6.2 with different avidity. Addition of
Nkx6.2-speciﬁc antibodies interfered with complex forma-
tion thus conﬁrming the presence of the shortened Nkx6.2
version in the respective complexes (Figure 4F).
Only Olig2-dependent activation, but not Nkx6.2-
dependent repression requires binding sites in U2
To determine whether the binding sites mediate the effects
of Olig2 and Nkx6.2 on the U2 enhancer, we mutated each
site (Figure 5A) and conﬁrmed by EMSA that the muta-
tions completely abolished binding of Olig2 and Nkx6.2,
respectively (Figure 5B and C). Then, we checked how
binding site mutations affect the Olig2-dependent activa-
tion of the U2-luc reporter in transiently transfected 33B
cells. In these experiments, we co-transfected E47 to boost
induction rates (Figure 5D). Qualitatively similar results
were obtained in transfections with Olig2 alone (data not
shown). Olig2-dependent induction rates for a U2-luc
reporter with mutant bHLH1 site were only 69% as
high as induction rates for the wild-type construct
(Figure 5D). Mutation of bHLH2 reduced activation
rates to 41%, mutation of bHLH4 even to 25% of
wild-type levels. It thus appears that all identiﬁed Olig2
binding sites contribute to the induction, however, to dif-
ferent extents. This conclusion was also conﬁrmed when
U2-luc reporters were analyzed that contained multiple
binding site mutations. Mutation of both bHLH1 and
bHLH2 reduced induction rates to similar levels as
mutation of bHLH2 alone. In contrast, all U2-luc report-
ers in which binding site mutations were combined with a
bHLH4 mutation had lost their Olig2 responsiveness com-
pletely. Among the three binding sites, bHLH4 therefore
appears to be the most important one. Interestingly, this is
the site within the conserved core of the U2 enhancer.
Analogous studies were also performed with the U2-luc
reporter to map the repressive effect of Nkx6.2 to the
identiﬁed binding sites. However, Nkx6.2 similarly re-
pressed wild-type U2-luc and mutant versions in which
either GTX1 or GTX2 were mutated (Figure 5E). Even
a U2-luc reporter in which both Nkx6.2 binding sites were
simultaneously mutated was still strongly repressed by
Nkx6.2 (Figure 5E). Similar results were obtained in trans-
fections in the presence or absence of co-transfected
Olig2 (compare Figure 5E to F). We conclude that the
potential Nkx6.2 binding sites are dispensable for
Nkx6.2-dependent repression.
There are many ways in which Nkx6.2 may exert its
repressive effect. Interaction with activating transcription
factors such as Olig2 and ensuing inactivation is one pos-
sibility. To investigate this possibility, we performed
co-immunoprecipitation experiments on extracts of 293
cells in which tagged versions of full-length Nkx6.2 and
1286 Nucleic Acids Research, 2011,Vol.39, No. 4Figure 4. The Sox10 U2 enhancer contains binding sites for Olig2 and Nkx6.2. (A) Sequence of mouse U2. Asterisks below the sequence indicate
positions that are fully conserved among mouse, human and chicken. The 190bp core region (gray box) is particularly enriched for conserved
positions. Putative binding sites are marked by a bar above the sequence. Potential Olig2 binding sites are designated as bHLH1–bHLH6, potential
Nkx6.2 binding sites as GTX1 and GTX2. Numbers on the right indicate the exact nucleotide position. (B) Transient transfections were performed in
33B oligodendroglioma with the U2 luc reporter and pCMV-based expression plasmids for Olig1 and E47 as indicated. Increasing amounts of
expression plasmid were used as indicated by the triangles (Olig1) and+versus+ +(E47). Luciferase activities in extracts from transfected cells were
determined in three experiments each performed in duplicates. The luciferase activity obtained for U2-luc in the absence of ectopic transcription
factor was arbitrarily set to 1. Fold inductions in the presence of transcription factors were calculated and are presented as mean±SD.
(C and D) EMSA was performed with radiolabeled double-stranded oligonucleotides encompassing the potential Olig2 binding sites bHLH1,
bHLH2 and bHLH4 (for sequence, see Figure 5A). Oligonucleotides were incubated in the absence ( ) or presence of extracts from 293 cells
that were either untransfected (control) or transfected with expression plasmids for myc-tagged versions of Olig1 or Olig2. Antibodies against the tag
(+Ab) were added as indicated. The Olig2-containing complex is marked by an arrowhead, the Olig1-containing complex by a dot and the
supershifted complexes by asterisks. All other complexes are unspeciﬁc as they were also obtained with the control extracts. (E and F) EMSA
was carried out with radiolabeled double-stranded oligonucleotides encompassing GTX1, GTX2 (for sequence, see Figure 5A) and the known
high-afﬁnity Nkx6.2 binding sequence HoxA5/A6 (Hox). Oligonucleotides were incubated in the absence ( ) or presence of extracts from 293
cells that were either untransfected (control) or transfected with expression plasmids for T7-tagged versions of full-length Nkx6.2 (ﬂ) or amino- and
carboxyterminally truncated Nkx6.2 (NC). Antibodies against the tag (+Ab) were added as indicated. The complex containing full-length Nkx6.2 is
marked by an arrowhead, the complex containing the NC version by a dot.
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6A). When precipitations were carried out with antibodies
against the tag of Olig2, Nkx6.2 was efﬁciently
co-precipitated if present in the extract (Figure 6B).
Under reciprocal conditions, Olig2 was similarly
co-precipitated with antibodies directed against the
Nkx6.2-speciﬁc tag (Figure 6C). Nkx6.2 could thus exert
part of its repressive effect by interacting and functionally
interfering with Olig2.
Using truncated versions of both Nkx6.2 and Olig2, we
also determined the interacting regions in both proteins.
Olig2 was divided into two fragments, an N-terminal part
that corresponds to amino acids 2–180 and a C-terminal
part that encompasses amino acids 181–323. Of these two
protein fragments, only the N-terminal part precipitated
Nkx6.2 (Figure 6D). This fragment contains the
DNA-binding bHLH domain.
Nkx6.2 was also divided into an N-terminal region (cor-
responding to amino acids 1–133) and a C-terminal part
(corresponding to amino acids 134–277) (Figure 6A). The
C-terminal fragment of Nkx6.2 interacted as efﬁciently
with Olig2 as the full-length protein, whereas Olig2
could not be detected in the precipitate of the
N-terminal fragment (Figure 6E). Considering that the
C-terminal part of Nkx6.2 contains the homeodomain,
our results suggest that the DNA-binding domains of
both proteins interact.
Olig2 binding is essential for activity of the U2 enhancer
in OLPs in vivo
As tissue culture and in vitro experiments pointed to Olig2
as a direct activator of U2, we set out to conﬁrm this
in vivo. First, we studied if Olig2 can bind to U2 in its
native chromatin context (Figure 7A). When 33B cells
were transfected with myc-tagged Olig2 and chromatin
immunoprecipitations were carried out with antibodies
directed against the myc tag, U2 was speciﬁcally recovered
in the precipitate, whereas a size-matched control region
located between U2 and the transcriptional start of the
Sox10 gene was not. Control IgG, furthermore, failed to
precipitate the U2 fragment.
While this ascertains that Olig2 can bind to the U2
enhancer in its native genomic context, it does not prove
that this is really the case in OLPs of the developing spinal
cord. To address this latter question, we performed add-
itional chromatin immunoprecipitations on spinal cord
from 18.5-dpc old embryos as OLPs are very prominent
in this tissue during late embryogenesis. Using anti-Olig2
antibodies, the U2 enhancer was again precipitated in sig-
niﬁcant amounts (Figure 6A). This contrasts with U5,a n
enhancer without activity in oligodendroglia (12). Neither
fragment was precipitated under identical conditions by
preimmune serum (Figure 7A). All available evidence
thus suggests that Olig2 is bound to the U2 enhancer in
OLPs.
Using anti-T7-tag antibodies, we were also able to
immunoprecipitate U2 from chromatin of 33B cells trans-
fected with T7-tagged Nkx6.2 (Figure 7A). Considering
that we found no evidence for a role of the potential
Nkx6.2 binding sites in U2 repression, we have to
conclude that Nkx6.2 binding to U2 is either irrelevant
for repression or, if relevant, that recruitment to U2
does not require direct binding to DNA, but is instead
mediated by interacting proteins such as Olig2.
Because bHLH4 had emerged as the most important
Olig2-binding site in vitro, we generated a transgenic con-
struct in which a lacZ reporter gene was driven by the
hsp68 minimal promoter in combination with a U2
version in which the bHLH4 site had been mutated
(U2mut-lacZ, Figure 7B). Apart from the bHLH4
mutation, this transgenic construct corresponded exactly
to the original U2-lacZ transgene (Figure7B) (12).
Transgenic lines were generated with the mutant construct
and activity of the mutant enhancer was determined by
X-gal staining in six transgenic lines. U2 had previously
been shown to be active throughout the PNS of mouse
embryos at 11.5 dpc. This activity remained unaffected
by the introduced mutation. Cranial ganglia, dorsal root
ganglia and peripheral nerves were similarly stained in
U2mut-lacZ and U2-lacZ transgenic embryos at this
early time and staining patterns were indistinguishable
(Figure 7C). This agrees well with the fact that Olig2 is
restricted in occurrence and function to the CNS.
Differences became only detectable at later time points
such as 14.5 (data not shown) and 16.5 dpc, when OLPs
were present (Figure 7D). These differences did not
concern the PNS expression which was still comparable
between U2-lacZ and U2mut-lacZ embryos. Within the
spinal cord, however, alterations were obvious. Whereas
spinal cords of U2-lacZ embryos had a speckled appear-
ance because of the transgene expression in OLPs, spinal
cords of U2mut-lacZ embryos either lacked X-gal staining
(progeny from 4 out of 6 analyzed founders) or exhibited a
weaker and more diffuse X-gal staining (progeny from 2
out of 6 analyzed founders). The weak diffuse staining was
furthermore speciﬁcally excluded from the marginal zone
which is rich in oligodendroglia (Figure 7D) arguing that
oligodendroglial expression of the U2 enhancer was also
abolished in these embryos by the introduced mutation.
Additional immunohistochemical studies conﬁrmed the
complete absence of b-galactosidase-positive cells in the
embryonic spinal cord of most embryos (Figure 7E, 4/6).
OLPs were, however, present in normal numbers as
indicated by the presence of Olig2 and Sox10-positive
cells (Figure 7E and data not shown). In those embryos
where diffuse staining was observed for the U2mut-lacZ
transgene, b-galactosidase was found to co-localize pre-
dominantly with NeuN-positive neurons rather than
with Sox10-positive or Olig2-positive OLPs (Figure 7F,
2/6). We therefore conclude that the Olig2 binding site
in the conserved core of the U2 enhancer is absolutely
essential for activity in OLPs. In its absence, the U2
activity in the CNS is either completely lost or reduced
and redirected to neurons.
DISCUSSION
Recently, we have identiﬁed the evolutionary conserved
U2 element in the distal 50-ﬂanking region of the Sox10
gene and characterized it as an enhancer with broad
1288 Nucleic Acids Research, 2011,Vol.39, No. 4Figure 5. Activation of the U2 enhancer requires binding sites for Olig2, whereas repression by Nkx6.2 is independent of binding sites. (A) Sequence
of oligonucleotides with wild-type and mutant binding sites for Olig2 and Nkx6.2. (B and C) EMSA was performed with wild-type and mutant
binding sites for Olig2 (B) and Nkx6.2 (C). Oligonucleotides were incubated in the absence ( ) or presence of extracts from 293 cells which were
either untransfected (control) or transfected with expression plasmids for tagged versions of Olig2 or Nkx6.2 NC. The position of the Olig2-speciﬁc
complex is highlighted by an arrowhead, the position of the Nkx6.2-speciﬁc complex by a dot. (D–F) Transient transfections were performed in 33B
oligodendroglioma with different versions of the U2 luc reporter and expression plasmids for Olig2, E47 (D), Nkx6.2 (E) or Olig2, E47 and Nkx6.2
(F) as indicated (+). The U2 luc reporter had either wild-type sequences (wt) or carried one or multiple mutations in the Olig2 binding sites
(bHLH1m, bHLH2m, bHLH4m, bHLH1/2m, bHLH1/4m, bHLH2/4m, bHLH1/2/4m) (D) or the Nkx6.2 (GTX1m, GTX2m, GTX1/2m) binding
sites (E and F). Luciferase activities in extracts from transfected cells were determined in three experiments each performed in duplicates. The
luciferase activity obtained for each reporter in the absence of ectopic transcription factor was arbitrarily set to 1. Fold inductions in the presence of
transcription factors were calculated and are presented as mean±SD. Statistically signiﬁcant (P 0.001) reporter gene activation by Olig2 and E47
(D) was obtained for the wt, 1m, 2m and 1/2m U2 luc reporters as determined by Student’s t-test. Nkx6.2-dependent repression was statistically
signiﬁcant (P 0.001) for all reporters in E and F.
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oligodendroglial activity in the CNS (12). Here, we
focused on the CNS-speciﬁc activity of the U2 enhancer
to understand how Sox10 expression is regulated in oligo-
dendroglia. By following expression of the transgenic
reporter in U2-lacZ mice, we show that activity of the
U2 enhancer is restricted to the precursor stage in the
oligodendrocyte lineage. As oligodendroglia underwent
terminal differentiation and expressed myelin genes, U2
was turned off. There was furthermore a signiﬁcant
delay between the onset of Sox10 expression in newly
speciﬁed OLPs and the onset of U2 activity. These
results argue that U2 is only partly responsible for the
Sox10 expression pattern in the oligodendrocyte lineage
and that there must be other not yet identiﬁed regulatory
regions that drive expression in newly speciﬁed oligo-
dendrocytes immediately after their speciﬁcation as well
as in differentiating and mature oligodendrocytes. The
seemingly simple, continuous expression of Sox10 in the
oligodendrocyte lineage thus results from the combined
activity of at least two regulatory regions. This is
somewhat reminiscent of the regulation of the MBP
gene which codes for a major component of the myelin
in both PNS and CNS. Correspondingly, MBP is ex-
pressed in Schwann cells of the PNS and oligodendrocytes
of the CNS. Additionally expression levels need to be
regulated over time in both cell types. In oligodendrocytes,
there is ﬁrst a phase of relatively low expression followed
by maximal expression during the phase of active myelin-
ation before downregulation occurs again in mature oligo-
dendrocytes to adjust for levels that are adequate for
myelin maintenance. In this case as well, the expression
pattern is the result of many different enhancers that are
spread over large distances of the MBP genomic locus
(28,29).
Activity of the mammalian U2 enhancer has also been
analyzed in zebraﬁsh and found to be present in
MBP-expressing oligodendrocytes (30). Oligodendroglial
U2 activity thus differs slightly between the two species
and appears extended in zebraﬁsh compared to mouse.
Mechanistically, it would be interesting to determine the
cause for this difference. The physiological relevance is
less clear, however, as the U2 enhancer is not conserved
in its sequence in the zebraﬁsh genome.
Another important ﬁnding of our study is the identiﬁ-
cation of Olig2 as a main activator of the U2 enhancer.
Olig2 is restricted in its expression to the CNS. Thus, it
can only be involved in regulating U2 activity in oligo-
dendroglia and not in Schwann cells and satellite glia of
the PNS. In the spinal cord, Olig2 is ﬁrst expressed ven-
trally in a deﬁned domain of the ventricular zone where it
is successively required for the speciﬁcation of motor
neurons and the speciﬁcation of OLPs (5,6). Its further
expression remains closely associated with the oligo-
dendrocyte lineage arguing that Olig2 continues to
function in these cells. Electroporations in the neural
tube of developing chicken embryos have furthermore
suggested that Olig2 is genetically upstream of Sox10
(6,23,26). By showing that Olig2 binds to the U2
enhancer and activates it both in vitro and in vivo,w e
here show for the ﬁrst time that the inﬂuence of Olig2
on Sox10 expression is direct. Our in vitro data further-
more suggest that Olig2 performs this function primarily
as a heterodimer with ubiquitous Class A bHLH proteins
such as E47. This ﬁts with the observation that Olig2 and
E47 can be co-immunoprecipitated and jointly bind to a
bHLH site in vitro (24,25). We furthermore provide
evidence both in vitro as well as in vivo that Olig2 activates
the U2 enhancer through several sites of which bHLH4 is
the predominant one. This site is part of the conserved U2
core and strongly conserved in mammalian and avian
species suggesting that U2 activity in oligodendroglia is
under Olig2 control in a wide variety of species.
It also needs to be emphasized that our study provides
overwhelming evidence for an activating role of Olig2.
This was by no means expected as several previous
studies had come to the conclusion that Olig2 primarily
functions as a transcriptional repressor during dorsoven-
tral patterning of the early spinal cord (16,31,32). Among
the few studies that had shown an activating role for Olig
proteins is the work by Li and colleagues, who had found
MBP expression in zebraﬁsh to be activated by Olig1 in
cooperation with Sox10 (33). In mouse, both Olig1 and
Olig2 synergistically activate MBP expression (15,33).
These species-speciﬁc differences notwithstanding, it can
be concluded that Olig proteins function both as repres-
sors and activators, probably depending on the transcrip-
tion factors with which they cooperate (34). Sox10 as one
of these transcription factors is both a target gene and an
interactor of Olig2, pointing to the intricate relationships
within the oligodendroglial transcriptional network.
As Olig2 is more active in OLPs, whereas the related
Olig1 performs its main function in differentiating oligo-
dendrocytes (5–8), Olig2 is physiologically more relevant
for U2 activation. Interestingly, we also found that Olig2
binds better than Olig1 in EMSA and is a much better U2
activator in transient transfection assays. We thus provide
molecular evidence that the two closely related Olig
proteins are not completely identical in their function
and possess at least partly different properties.
While our data show that oligodendroglial expression is
under control of Olig2, they do not reveal how Olig2
causes the initial induction of Sox10 in newly speciﬁed
OLPs as this initial induction does not depend on U2.
Again we would argue that Olig2 function is context de-
pendent and that the initial induction requires a
transcriptional partner which is unable to function on U2.
The loss of a required partner protein may also explain
the decline of U2 activity once OLPs turn into myelinating
oligodendrocytes. However, other mechanisms also con-
tribute. It is known for instance that mature oligodendro-
cytes have lower levels of Olig2 than OLPs. The transient
increase of nuclear Olig1 during the active phase of
terminal differentiation probably has very little inﬂuence
on U2 activity as Olig1 is not an efﬁcient U2 activator. In
mature oligodendrocytes, Olig1 is furthermore mainly
cytoplasmic and thus not active as a transcription factor
(8). The reduced amounts of Olig2 will be distributed
among several regulatory regions and protein complexes.
As we have shown in this study, one of the complexes
that can form contains Olig2 and Nkx6.2. Because
of the restricted expression pattern of Nkx6.2 in the
1290 Nucleic Acids Research, 2011,Vol.39, No. 4oligodendrocyte lineage (20), this complex can form in
mature oligodendrocytes but not in OLPs. Considering
further the inhibitory inﬂuence of Nkx6.2 on U2 activity,
it seems plausible that Nkx6.2 is involved in the
downregulation of U2 activity in oligodendrocytes
through inactivation of Olig2. The same mechanism may
also explain why U2 is not immediately induced in newly
speciﬁed OLPs. At that time, Nkx6.2 is about to be
down-regulated, but still present (21,22). Nkx6.1 exhibits
the same expression pattern during this early time, and also
represses U2 activity. Their joint presence may prevent U2
from being activated and require an independent, Nkx6.2
insensitive enhancer for Sox10 induction in this earliest
phase of oligodendroglial development. U2 would then
become active after disappearance of Nkx6.2 and Nkx6.1.
In contrast to Nkx6.2 and Nkx6.1, Nkx2.2 did not
repress U2 activity. This ﬁts with the observation that
the U2-lacZ transgene is co-expressed with Nkx2.2 in
late stage OLPs. It also indicates that the two groups of
Nkx proteins perform at least partially different roles
during oligodendrocyte development.
Analysis in transgenic mice indicates that the Olig2
binding site is absolutely essential for U2 activity in
OLPs, but dispensable for U2 activity in PNS glia. It
will be interesting to deﬁne in future experiments the
cis-acting elements within U2 for PNS expression and to
see how they are arranged relative to the Olig2 binding site
and to other binding sites that are additionally required
for oligodendroglial expression. The presence of such add-
itional sites is expected as enhancer activity is usually de-
pendent on the combined activity of several transcription
factors. The fact that U2 activity does not completely
mirror Olig2 occurrence further corroborates the need
for additional factors. Very often, cooperating transcrip-
tion factors are bound in close vicinity to each other on
the enhancer that they jointly activate. Inspection of the
sequence around the identiﬁed Olig2 site, however, did not
point to obvious candidates for such interacting transcrip-
tion factors. Their future identiﬁcation and the character-
ization of their interplay with Olig2 will further deepen
our insight into the transcriptional network that drives
oligodendrocyte development.
Figure 6. Olig2 and Nkx6.2 interact via their DNA-binding domains. (A) Schematic representation of the domain structure of Olig2 and Nkx6.2 (ﬂ)
and the N-terminal (N) and C-terminal (C) parts of each protein used in co-immunoprecipitations. Numbers indicate the amino acid positions that
mark end or beginning of the proteins and its domains. (B and C) Co-immunoprecipitations were performed on extracts containing full-length
versions of myc-tagged Olig2, T7-tagged Nkx6.2 or both with antibodies directed against the myc-tag (a-myc) (B) and the T7-tag (a-T7) (C) as
indicated above the panels. (D) Additionally, co-immunoprecipitations were carried out on extracts containing the myc-tagged full-length Olig2 (ﬂ),
its N-terminal (N) or C-terminal (C) parts in the presence of T7-tagged Nkx6.2 and antibodies directed against the myc-tag. (E) In the reverse
experiment, T7-tagged full-length Nkx6.2 (ﬂ), as well as its N-terminal (N) or C-terminal (C) parts were tested for their ability to precipitate
full-length myc-tagged Olig2 in co-immunoprecipitations with antibodies directed against the T7-tag. Proteins in the input (1/10 in B, C and 1/20
in D, E) and in the precipitate were visualized by western blotting using the two tag-speciﬁc antibodies as indicated on the left of each panel in B–E.
Nucleic Acids Research,2011, Vol.39, No. 4 1291Figure 7. Olig2 binding is essential for U2 activity in vivo.( A) Chromatin immunoprecipitation was performed on 33B cells (upper panels) trans-
fected with myc-tagged Olig2 (myc-Olig2) or T7-tagged Nkx6.2 (T7-Nkx6.2), and on spinal cords from four 18.5 dpc-old wild-type mice (lower
panels) in the absence (buffer) and presence of antibodies (PI, preimmune serum; a-tag, anti-myc or anti-T7 tag antibodies; a-Olig2, anti-Olig2
antibodies). PCR was applied on the immunoprecipitate to detect U2, a non-conserved region between U2 and the transcriptional start of Sox10
(neg) and U5. These regions of the Sox10 locus were also ampliﬁed from 1/10 of the material used for immunoprecipitation (input). (H2O), water
control. (B) Schematic representation of the transgenic constructs consisting of U2 in wild-type (U2) or mutant (U2mut) version, the hsp68 minimal
promoter (hsp), the lacZ marker gene (lacZ) and a SV40 polyA signal (pA). (C and D) LacZ activity was detected colorimetrically using X-gal substrate
on whole embryos at 11.5 dpc (C) and on transverse sections (forelimb level) at 16.5 dpc (D) in embryos carrying the U2-lacZ transgene in wild-type or
mutant version. The whole mount stainings at 11.5 dpc (C) were documented from the side and from the back. All transgenic lines carrying the
U2mut-lacZ transgene looked similar at this stage. Transverse sections at 16.5 dpc (D) exhibited some differences. In most U2mut-lacZ transgenic lines
(4/6), X-gal staining had completely disappeard from the spinal cord. A minority (2/4) showed a residual weak and diffuse X-gal staining. (E and F)
Co-immunohistochemistry was performed at 16.5 dpc on transverse spinal cord sections of the two types of U2mut-lacZ transgenic embryos (4/6 and
2/6) using antibodies directed against b-galactosidase (in green) in combination with antibodies directed against the oligodendroglial markers Sox10
and Olig2 and the neuronal marker NeuN (all in red) as indicated. Size bars correspond to 1mm in C and 100mm in D and E.
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